Sequential therapy or triple therapy for helicobacter pylori infection: Systematic review and meta-analysis of randomized controlled trials in adults and children

Luigi Gatta, Nimish Vakil, Gioacchino Leandro, Francesco Di Mario, Dino Vaira

Research output: Contribution to journalArticle

236 Citations (Scopus)

Abstract

OBJECTIVES: Eradication rates with triple therapy (TT) for Helicobacter pylori infection have declined to unacceptable levels. Sequential therapy (ST) is a novel treatment that has shown promise in several controlled trials. Our aim was to assess the efficacy of ST in adults and children compared with that of TT by performing a systematic review and meta-analysis. METHODS: We performed an electronic search of the following: Cochrane Trial Register (until Issue 4, 2008), MEDLINE (1966 to 21 October 2008), EMBASE (1980 to 21 October 2008), and abstracts from the major US, European, and Asian gastroenterology conferences. Randomized controlled trials (RCTs) and controlled clinical trials with a parallel group design comparing the ST with a TT lasting at least 7 days were used. RESULTS: Ten RCTs enrolled 3,006 adult patients and the odds ratio (OR) for eradication of H. pylori with ST compared with TT was 2.99 (95% confidence interval (CI): 2.47-3.62), giving a number needed to treat (NNT) of 6 (95% CI: 5-7) favoring ST. There was no publication bias. The OR for eradication with ST compared with 10-day TT was 2.92 (95% CI: 1.95-4.38), yielding an NNT of 8 (95% CI: 6-12), favoring ST. In patients with clarithromycin resistance, the OR for eradication with ST was 10.21 (95% CI: 3.01-34.58) compared with TT, but the numbers studied are small. Three RCTs enrolled 260 children and adolescents, and the OR for eradication was 1.98 (95% CI: 0.96-4.07). There was no difference in the rate of side effects between the ST and the TT (OR, 1.01; 95% CI: 0.78-1.30). CONCLUSIONS: ST appears to be better than TT in the eradication of H. pylori. This is a promising therapy, but further trials are needed in other European countries and North America before it can be recommended as a first-line treatment.

Original languageEnglish
Pages (from-to)3069-3079
Number of pages11
JournalAmerican Journal of Gastroenterology
Volume104
Issue number12
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Helicobacter Infections
Helicobacter pylori
Meta-Analysis
Randomized Controlled Trials
Therapeutics
Confidence Intervals
Odds Ratio
Numbers Needed To Treat
Publication Bias
Clarithromycin

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Sequential therapy or triple therapy for helicobacter pylori infection : Systematic review and meta-analysis of randomized controlled trials in adults and children. / Gatta, Luigi; Vakil, Nimish; Leandro, Gioacchino; Di Mario, Francesco; Vaira, Dino.

In: American Journal of Gastroenterology, Vol. 104, No. 12, 12.2009, p. 3069-3079.

Research output: Contribution to journalArticle

@article{e1635ee3aba24e709c04d84a173d1a94,
title = "Sequential therapy or triple therapy for helicobacter pylori infection: Systematic review and meta-analysis of randomized controlled trials in adults and children",
abstract = "OBJECTIVES: Eradication rates with triple therapy (TT) for Helicobacter pylori infection have declined to unacceptable levels. Sequential therapy (ST) is a novel treatment that has shown promise in several controlled trials. Our aim was to assess the efficacy of ST in adults and children compared with that of TT by performing a systematic review and meta-analysis. METHODS: We performed an electronic search of the following: Cochrane Trial Register (until Issue 4, 2008), MEDLINE (1966 to 21 October 2008), EMBASE (1980 to 21 October 2008), and abstracts from the major US, European, and Asian gastroenterology conferences. Randomized controlled trials (RCTs) and controlled clinical trials with a parallel group design comparing the ST with a TT lasting at least 7 days were used. RESULTS: Ten RCTs enrolled 3,006 adult patients and the odds ratio (OR) for eradication of H. pylori with ST compared with TT was 2.99 (95{\%} confidence interval (CI): 2.47-3.62), giving a number needed to treat (NNT) of 6 (95{\%} CI: 5-7) favoring ST. There was no publication bias. The OR for eradication with ST compared with 10-day TT was 2.92 (95{\%} CI: 1.95-4.38), yielding an NNT of 8 (95{\%} CI: 6-12), favoring ST. In patients with clarithromycin resistance, the OR for eradication with ST was 10.21 (95{\%} CI: 3.01-34.58) compared with TT, but the numbers studied are small. Three RCTs enrolled 260 children and adolescents, and the OR for eradication was 1.98 (95{\%} CI: 0.96-4.07). There was no difference in the rate of side effects between the ST and the TT (OR, 1.01; 95{\%} CI: 0.78-1.30). CONCLUSIONS: ST appears to be better than TT in the eradication of H. pylori. This is a promising therapy, but further trials are needed in other European countries and North America before it can be recommended as a first-line treatment.",
author = "Luigi Gatta and Nimish Vakil and Gioacchino Leandro and {Di Mario}, Francesco and Dino Vaira",
year = "2009",
month = "12",
doi = "10.1038/ajg.2009.555",
language = "English",
volume = "104",
pages = "3069--3079",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Sequential therapy or triple therapy for helicobacter pylori infection

T2 - Systematic review and meta-analysis of randomized controlled trials in adults and children

AU - Gatta, Luigi

AU - Vakil, Nimish

AU - Leandro, Gioacchino

AU - Di Mario, Francesco

AU - Vaira, Dino

PY - 2009/12

Y1 - 2009/12

N2 - OBJECTIVES: Eradication rates with triple therapy (TT) for Helicobacter pylori infection have declined to unacceptable levels. Sequential therapy (ST) is a novel treatment that has shown promise in several controlled trials. Our aim was to assess the efficacy of ST in adults and children compared with that of TT by performing a systematic review and meta-analysis. METHODS: We performed an electronic search of the following: Cochrane Trial Register (until Issue 4, 2008), MEDLINE (1966 to 21 October 2008), EMBASE (1980 to 21 October 2008), and abstracts from the major US, European, and Asian gastroenterology conferences. Randomized controlled trials (RCTs) and controlled clinical trials with a parallel group design comparing the ST with a TT lasting at least 7 days were used. RESULTS: Ten RCTs enrolled 3,006 adult patients and the odds ratio (OR) for eradication of H. pylori with ST compared with TT was 2.99 (95% confidence interval (CI): 2.47-3.62), giving a number needed to treat (NNT) of 6 (95% CI: 5-7) favoring ST. There was no publication bias. The OR for eradication with ST compared with 10-day TT was 2.92 (95% CI: 1.95-4.38), yielding an NNT of 8 (95% CI: 6-12), favoring ST. In patients with clarithromycin resistance, the OR for eradication with ST was 10.21 (95% CI: 3.01-34.58) compared with TT, but the numbers studied are small. Three RCTs enrolled 260 children and adolescents, and the OR for eradication was 1.98 (95% CI: 0.96-4.07). There was no difference in the rate of side effects between the ST and the TT (OR, 1.01; 95% CI: 0.78-1.30). CONCLUSIONS: ST appears to be better than TT in the eradication of H. pylori. This is a promising therapy, but further trials are needed in other European countries and North America before it can be recommended as a first-line treatment.

AB - OBJECTIVES: Eradication rates with triple therapy (TT) for Helicobacter pylori infection have declined to unacceptable levels. Sequential therapy (ST) is a novel treatment that has shown promise in several controlled trials. Our aim was to assess the efficacy of ST in adults and children compared with that of TT by performing a systematic review and meta-analysis. METHODS: We performed an electronic search of the following: Cochrane Trial Register (until Issue 4, 2008), MEDLINE (1966 to 21 October 2008), EMBASE (1980 to 21 October 2008), and abstracts from the major US, European, and Asian gastroenterology conferences. Randomized controlled trials (RCTs) and controlled clinical trials with a parallel group design comparing the ST with a TT lasting at least 7 days were used. RESULTS: Ten RCTs enrolled 3,006 adult patients and the odds ratio (OR) for eradication of H. pylori with ST compared with TT was 2.99 (95% confidence interval (CI): 2.47-3.62), giving a number needed to treat (NNT) of 6 (95% CI: 5-7) favoring ST. There was no publication bias. The OR for eradication with ST compared with 10-day TT was 2.92 (95% CI: 1.95-4.38), yielding an NNT of 8 (95% CI: 6-12), favoring ST. In patients with clarithromycin resistance, the OR for eradication with ST was 10.21 (95% CI: 3.01-34.58) compared with TT, but the numbers studied are small. Three RCTs enrolled 260 children and adolescents, and the OR for eradication was 1.98 (95% CI: 0.96-4.07). There was no difference in the rate of side effects between the ST and the TT (OR, 1.01; 95% CI: 0.78-1.30). CONCLUSIONS: ST appears to be better than TT in the eradication of H. pylori. This is a promising therapy, but further trials are needed in other European countries and North America before it can be recommended as a first-line treatment.

UR - http://www.scopus.com/inward/record.url?scp=72949096113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949096113&partnerID=8YFLogxK

U2 - 10.1038/ajg.2009.555

DO - 10.1038/ajg.2009.555

M3 - Article

C2 - 19844205

AN - SCOPUS:72949096113

VL - 104

SP - 3069

EP - 3079

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 12

ER -